What's in Ocular Therapeutix, Inc.'s pipeline?

Ocular Therapeutix, Inc. has 12 drugs in our index: 1 marketed, 0 filed, 5 in Phase 3, 4 in Phase 2, 2 in Phase 1.

Which companies overlap with Ocular Therapeutix, Inc.'s portfolio?

Top competitors by shared drug class: Pfizer, Wyeth is now a wholly owned subsidiary of Pfizer, AstraZeneca, Centre Leon Berard, Jiangsu HengRui Medicine Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ocular-therapeutix-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Ocular Therapeutix, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ocular Therapeutix, Inc. pipeline: 1 marketed, 0 filed, 5 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 5 Phase 3 4 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Dexamethasone, 0.4mg	Dexamethasone, 0.4mg	marketed
Dextenza Ophthalmic Insert	Dextenza Ophthalmic Insert	phase 3	Corticosteroid	Glucocorticoid receptor	Ophthalmology
Punctum Plug	Punctum Plug	phase 3			Ophthalmology
Ophthalmic Insert	Ophthalmic Insert	phase 3	Ophthalmic insert / sustained-release device		Ophthalmology
OTX-TKI	OTX-TKI	phase 3	Tyrosine kinase inhibitor	Multiple receptor tyrosine kinases (RTKs)	Ophthalmology
OTX-TKI (axitinib implant)	OTX-TKI (axitinib implant)	phase 3	tyrosine kinase inhibitor	VEGFR	Oncology

Therapeutic area mix

Ophthalmology · 4
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 3 shared drug classes
Wyeth is now a wholly owned subsidiary of Pfizer · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Centre Leon Berard · 2 shared drug classes
Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes
Sun Yat-sen University · 2 shared drug classes
Akeso · 2 shared drug classes
Air Force Military Medical University, China · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ocular Therapeutix, Inc.:

Cite this brief

Drug Landscape (2026). Ocular Therapeutix, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ocular-therapeutix-inc. Accessed 2026-05-16.